Mary Caffrey

Community Oncology Alliance AI Playbook powers digital health practice transformation, guiding teams to choose AI partners, protect data, and expand efficient care.

Reconstructed Kaplan-Meier data benchmark durability of CAR-T, bispecific antibodies, and zanubrutinib combos for relapsed follicular lymphoma.

Chemo-free zanubrutinib plus rituximab in phase 3 MANGROVE cuts progression/death risk 43% vs BR for frontline mantle cell lymphoma.

As CAR T-cell therapy expands into outpatient and community settings, Reimagine Care and The Center for Cancer and Blood Disorders are creating a monitoring infrastructure to support patients and caregivers alike.

Kazia Therapeutics advances paxalisib, a dual PI3K/mTOR inhibitor, into triple-negative breast cancer, boosting immunotherapy responses with early promising data.

SYNC-T from Syncromune delivers a 4-part localized immunotherapy regimen for metastatic prostate cancer, showing high response rates with low toxicity.

At ESMO GI, Merck’s next-generation KRAS-inhibitor calderasib plus EGFR-targeting cetuximab and chemotherapy produce remarkable progression-free survival results for patients with previously untreated colorectal cancer.

ViroMissile shares phase 1 IDOV-Safe oncolytic virus results, showing IV activity in pMMR/MSS metastatic colorectal cancer and fueling US phase 2 plans.

emtelligent turns unstructured data into coded clinical insights, powering Optum and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions.

FDA clears hands-free on-body injector for isatuximab in multiple myeloma, cutting treatment time and reactions while matching IV efficacy.